HOME >> MEDICINE >> NEWS
U of MN earns $7.9 million NIH grant to expand neuroscience research

The University of Minnesota's Center for Magnetic Resonance Research (CMRR) was one of four institutions in the country to receive a NIH Blueprint Grant for Neuroscience Research.

The $7.9 million award (approximately $1.5 million each year for five years) will be used to open up the CMRR's imaging technology to more neuroscience researchers across departments in the University. CMRR's application received the highest score of the 40 institutions that applied for the grant.

"This grant is a result of all of our work on brain sciences at the CMRR," said Kamil Ugurbil, Ph.D., director of CMRR and professor of radiology, neuroscience and medicine at the University of Minnesota Medical School. "Now we will be able to expand it quite a bit by creating an environment that allows our technology to be used by the larger neuroscience community."

CMRR is an interdisciplinary research laboratory that houses state-of-the-art magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) equipment for use in biomedical research. The central aim of the research conducted in CMRR is to develop non-invasive MR methods and technology for the acquisition of functional, physiological, and biochemical information in intact biological systems, and to use this capability to probe biological processes in health and disease.

Development of functional brain imaging and imaging of Alzheimer's plaques are examples of first-time accomplishments that are credited to the unique high magnetic field MR research carried out in CMRR. CMRR's magnets are six times as strong as most MRI machines found in a typical clinical setting.

The NIH Blueprint for Neuroscience Research grants were developed as a partnership between 15 NIH institutes and centers to accelerate neuroscience research. As opposed to funding individual research projects, these grants encourage the creation of centralized infrastructures that will expand and facilitate neuroscience research by
'"/>

Contact: Sara E. Buss
buss@umn.edu
612-624-2449
University of Minnesota
17-Oct-2006


Page: 1 2

Related medicine news :

1. Tennessee researcher earns Komen grant to study depression and breast cancer
2. Northwestern Memorial earns magnet status for nursing excellence
3. Surgical critical care team at HUP earns Beacon Award for Critical Care Excellence
4. UK College of Public Health earns national accreditation
5. Damon Runyon renews its $2.25 million investment to support young clinical cancer investigators
6. Split the difference: Pill-splitting study looks at cost-saving step that could be used by millions
7. FPG receives $8 million for autism research
8. CIRM awards $3.79 million to Burnham Institute
9. The Burroughs Wellcome Fund awards $8 million to infectious disease investigators
10. Scripps Research awarded $17 million for adult stem cell use to treat eye diseases
11. Mayor of New York proposes preventing 100 million deaths from tobacco

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: earns million NIH grant expand neuroscience research

(Date:10/22/2014)... (PRWEB) October 22, 2014 On Saturday, October ... its fourth annual family health and fitness fair ¡Vive tu ... physical activity and good nutrition for better health and wellness ... which is free and open to the public, will be ... Brownsville, from 9:00 am to 1:00 pm. , “¡Vive ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 For Dr. Iris ... make money; it’s an extension of her life’s mission. Her ... venture as the owner of FirstLight HomeCare, make it clear ... important to me that my work makes a difference in ... an entrepreneurial spirit, so after much research, I felt ready ...
(Date:10/22/2014)... The Louis W. Sullivan Institute ... distribute health information technology innovation to transform quality ... development of six key guiding principles of patient-centered ... These are an expansion of the Institute of ... is respectful of and responsive to individual patient ...
(Date:10/22/2014)... Best Cheap Hosting USA is among ... site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) ... from around the world. , “iPower is one of ... is providing various kinds of useful products for new ... offering excellent customer service and a number of features ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Lintelus, Inc., ... Sr. Vice President of Sales, will be speaking on ... Meetings Technology Expo on October 28, at the Holiday ... hosting a booth as well as a Tech Demo ... Meeting can create a more engaging event experience. , ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2
(Date:10/22/2014)... 22, 2014 Sanomedics International Holdings, Inc. (OTCQB: ... Global Research & Data Services, demand for thermometers is ... through 2018, as demand for more accurate digital thermometers ... the world,s largest market for thermometers, and one of ... Sanomedics International Holdings, Inc. Sanomedics International Holdings ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... and dermatology therapies. PV-10, its novel investigational drug for ... the potential for systemic side effects. Its oncology focus ... liver. Provectus has completed phase 2 trials of PV-10 ... as a topical treatment for atopic dermatitis and psoriasis. ...
(Date:10/22/2014)... LA JOLLA, Calif. , Oct. 22, ... RGLS ), a biopharmaceutical company leading ... targeting microRNAs, today announced that it has ... from an ongoing clinical study evaluating RG-101, ... for the treatment of hepatitis C virus ...
Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
Cached News: